Royalty Report: Medical, Cannabis, Diagnostic – Collection: 359498

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Medical
  • Cannabis
  • Diagnostic
  • DNA
  • Test/Monitoring
  • Device
  • Diabetes Treatment

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 359498

License Grant
Licensor grants Licensee an exclusive license to use the Authored Work referred to as 'Licensor Rapid Cannabis Recommendation.' Uniquely for Customer under their Licensing Agreement, and in return for their Licensing fee paid, will deliver to Customer for use with their customers a branded and customized DNA Kit package. This grant of license and technology applies to the following the exclusive right to
1. Licensee branded – DNA Kit
2. Licensor Rapid Cannabis Recommendation Application as defined in Agreement
3. Licensee Custom AI Interface to be owned by Licensee exclusive to cannabis and hemp industry only
License Property
That package will include the proprietary Licensor DNA kit, and all associated services required to produce an 'individual-specific' set of recommendations for their health and wellness, further customized to align Licensor recommendations with Customer products to ensure Customer can enhance their customer relationship by uniquely offering a way to learn more about their own DNA, their health and wellness and how Customer specific products relating to the use of cannabis and hemp will best help them achieve optimal health and wellness condition. Licensor retains title and ownership of the Authored Wark and derivative works will be assigned to Licensor by Licensee.

Licensor Rapid Cannabis and Hemp Recommendation Engine
– Provides predictive dosing, strain selection and timing using a 48-hour chip read data set.
– Provides a pipeline for faster recommendation via use of 'Short' data. Interfaces with Pre-Trained AI algorithms to advance 'Short' data.
– Includes large data tool set where applicable.
– Uses Whole Genome as Training Set reference to Impute AI based FGX for short reads.

Field of Use
The Licensee tests individual human genomes through proprietary technology it calls Multiomic Advanced Technology™ (“MAT”) and then uses, and uses the aggregation of individual data obtained to construct platforms (“Platforms”) or engines (“Engines”) to predict an individual’s predisposition to specific diseases or syndrome (“Predictive Multiomics™).

Field of use is in the medical industry for the gathering of human genome DNA, sequencing of that DNA, alignment and processing of that DNA sequence through Licensors proprietary Artificial Intelligence (AI) to provide a specific end result to include specific health, wellness, exercise, sleep and stress management recommendations for each individual whose DNA was processed, to improve their health and wellness, and to offer them reasonable recommendations to improve their health and wellness.

IPSCIO Record ID: 360691

License Grant
Assignor transferred the patent rights for MAT to the Assignee.
License Property
Multiomic Advanced Technologyâ„¢ (MAT)  a test that tests individual human genomes through this proprietary technology and uses the aggregation of individual data obtained to construct platforms or engines to preduct diseases. MAT is not limited to analysis of the human genome. It is also capable of analyzing the individual’s multiomics.  Multiomics is part of a revolution in science and medicine birthed by groundbreaking scientific advancements in 2001 when DNA was decoded. Multiomics consists in analyzing not only the human genome, but other “omics,” including viromes (viruses inside the body), proteomics (proteins) and metabolites. The human genome is a complete set of nucleic acid sequences for humans, encoded as DNA within the 23 chromosome pairs in cell nuclei and in a small DNA molecule.

Patent Application 2021/0104322 published on April 8, 2021, Personal Wellness Recommendation Engine, originally patent application 16/938,791

Field of Use
Field of use is to predict an individual’s predisposition to specific diseases or syndrome (Predictive Multiomics™).

IPSCIO Record ID: 359501

License Grant
Licensor grants Licensee an exclusive license to use the Licensor Technology within the territories of United States, Australia and others as approved in writing by Licensor.
License Property
Intellectual property related to the Cannabis product and Frelii Rapid Cannabis Recommendations product, as more fully set forth in a certain Intellectual Property Asset Purchase Agreement.

Intellectual Property listed in the Asset Purchase Agreement shall mean the right, title, and interest in and to a certain software, technology and data developed and owned by Seller relating to products and services for the gathering and sequencing of human genome DNA, alignment and processing of such DNA through Seller’s proprietary Artificial Inteligence (“AI”) in order to provide reports and analysis to customers (the Frelii Technology).

The Frelii Technology consists of the following components and the data and configurations which enable them
1. U.S. Provisional Utility Patent Application; Atty. Docket No. 46223-0002P01
2. NAVII – A set of software components which implement AI and other technologies to process, analyze, and extend sequenced human DNA data
3. Core & API – software and data which extend NAVII and manages the workflow and pipelines necessary for NAVII to interact with other Frelii Technology components
4. Integrations – software implemented to allow interaction with systems and data from labs, partners and customers
5. Products – Application software and product meta-data to generate reports and user interactions for commercial use. Products exist in the Frelii Technology in various states for
a. Cannabis – genetic interpretation and dosing for individuals;
b. Genetic Analysis – interpretations, reporting and web-based interactions of more than a dozen additional areas of analysis for individual genetics; and
c. Health & Wellness – interpretation, reporting and web-based interactions for analyzing individual genetics for the applications of diet, nutrition, exercise and nutraceuticals;
1. Executables, Source codes, use codes, or other coding required to utilize and implement Artificial Intelligence pursuant to this Agreement.
2. All Authored Work as set forth in the License Agreement relating to certain Artificial Intelligence;
3. The “Frelii Rapid Cannabis Recommendation” as set forth in the License Agreement;
4. Frelii work product and clinical trial data; and
5. Goodwill

Field of Use
Field of use is used in the medical industry relating to DNA, wellness, and cannabis.

IPSCIO Record ID: 359499

License Grant
Seller hereby agrees to sell, convey, transfer, assign, grant and deliver to Purchaser, and Purchaser hereby agrees to purchase, acquire and accept from Seller at the Closing (as hereinafter defined) all of Seller’s right, title and interest in and to the Intellectual Property, free and clear of all liabilities, obligations, pledges, security interests, liens, defenses, contractual commitments, claims, setoffs, equities or other encumbrances or charges (collectively, the Encumbrances) other than as expressly set forth herein.
License Property
Intellectual Property shall mean all of Seller’s right, title, and interest in and to a certain software, technology and data developed and owned by Seller relating to products and services for the gathering and sequencing of human genome DNA, alignment and processing of such DNA through Seller’s proprietary Artificial Inteligence (“AI”) in order to provide reports and analysis to customers (the Licensor Technology).

The Licensor Technology consists of the following components and the data and configurations which enable them
1. U.S. Provisional Utility Patent Application; Atty. Docket No. 46223-0002P01
2. NAVII – A set of software components which implement AI and other technologies to process, analyze, and extend sequenced human DNA data
3. Core & API – software and data which extend NAVII and manages the workflow and pipelines necessary for NAVII to interact with other Licensor Technology components
4. Integrations – software implemented to allow interaction with systems and data from labs, partners and customers
5. Products – Application software and product meta-data to generate reports and user interactions for commercial use. Products exist in the Licensor Technology in various states for
a. Cannabis – genetic interpretation and dosing for individuals;
b. Genetic Analysis – interpretations, reporting and web-based interactions of more than a dozen additional areas of analysis for individual genetics; and
c. Health & Wellness – interpretation, reporting and web-based interactions for analyzing individual genetics for the applications of diet, nutrition, exercise and nutraceuticals;
1. Executables, Source codes, use codes, or other coding required to utilize and implement Artificial Intelligence pursuant to this Agreement.
2. All “Authored Work” as set forth in the License Agreement relating to certain Artificial Intelligence;
3. The “Licensor Rapid Cannabis Recommendation” as set forth in the License Agreement;
4. Licensor work product and clinical trial data; and
5. Goodwill

Intellectual Property with respect to the above shall include, without limitation (i) all information, intellectual property inventions, patent applications, patents, trademarks, works of authorship, designs, copyrights, copyright applications, copyright registrations, Trade Secrets and Confidential Information, know-how, show-how, substances, recipes, formulas, compositions, equipment, apparatuses, techniques, samples, prototypes, models, methods, practices, processes, processes, process parameters, research and development information, notes, books, writings or other documents, software, algorithms, flow charts, data flow diagrams, state transition diagrams, contact diagrams, technical plans and designs, data, blueprints, technical information, ideas, specifications, strategies, drawings, computer programs, client or third party information, methods of manufacture, distribution, marketing, strategy and sale, and general business operations, including customer lists, pricing data, financial statements, and business plans including, but not limited to, improvements, changes, and modifications to the foregoing, relating to the Intellectual Property, which is not generally known or readily ascertainable and/or not already known to Purchaser, and which is provided to Purchaser by Seller; (ii) any right to use or exploit any of the foregoing, and (iii) any other proprietary right, whether arising under the laws of the United States or any other country.

Trade Secret shall mean Seller’s formula, pattern, compilation, device, method, technique, or process, tangible or intangible, in connection with the Intellectual Property, wherein Seller derives independent economic value, actual or potential from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use, and is the subject of efforts that are reasonable under the circumstances to maintain its secrecy and/or which qualifies as a trade secret within the meaning of the California Uniform Trade Secrets Act and the Defend the Trade Secrets Act.

Field of Use
Field of use is used in the medical industry relating to DNA, wellness, and cannabis.

IPSCIO Record ID: 359500

License Grant
Licensor hereby grants to Licensee an exclusive license to develop the Engine and a non-exclusive license to the Licensor Technology in the Licensed Territory for Licensed Products in the Field of Use.
License Property
Engine shall mean technology customized  for the early diagnosis for the predisposition for Type I and Type II diabetes, and the physical characteristics of an individual which are the specific precursors of Type I and Type II diabetes.

Licensed Products shall mean the Engine, together with those aspects of the Licensor Technology integrated therein, in connection with the Test Kit and the Processing.

Licensor Technology shall mean all patents or applications thereto of any country or region, owned or controlled by Licensor Health on the Effective Date of this Agreement or during the term of this Agreement, or any other proprietary technology, trade secrets, or trademark, where the making, having made, using or selling of Licensed Products would constitute an infringement thereof, for specific technologies resulting in products and services for the gathering of human genome DNA data to generate a specific end result report to individuals regarding their DNA and its relation to specific diseases and medical conditions, as well as any divisionals, continuations, continuations-in-part, extensions or reissues thereof, any patents granted on any of the foregoing and any foreign patents or applications corresponding to any of the foregoing.

Field of Use
Licensee is devoted to improving diabetes detection and treatment by utilizing GATC Health’s proprietary Multiomics Advanced Technology™ (MAT). This diabetes-specific instance of this technology will help the company deliver on three goals First, unlocking the genomic and environmental triggers for type 1 and type 2 diabetes so that targeted interventions can stop the diseases before they start. Second, to provide patients and their clinicians with precision prognostics to accurately predict disease-related outcomes. Third, to greatly accelerate drug discovery and treatment validation, providing actionable direction in record time and with unmatched accuracy for therapeutics development partners.

Field of Use shall mean any use of the Engine in Licensed Products for the treatment of diabetes.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.